Experts in the generation of real-world data and shaping of real-world evidence

Conducting multi-country real-world observational studies and healthcare database analyses for over 25 years, our services are grounded in the extensive heritage afforded by Adelphi’s proprietary Disease Specific Programmes™ and supported by the subsequent expansion of our real-world evidence services to meet pharmaceutical client needs.

We provide a unique range of real-world insights involving physicians, patients, caregivers and payers; with insights achieved through our market-leading Disease Specific Programmes™, tailored non-interventional studies, international secondary database analyses and expert market access strategy.

Adelphi Real World is a dedicated team of more than 200 professionals; we provide support and guidance for our clients across all areas of real-world evidence implementation.

Our scope of work and experience covers the complete lifecycle of a compound. Our global coverage ensures our evidence can shape all levels of insight from multi-country strategy through to domestic, tactical implementation.

Our Real World

Our real-world evidence is generated through the study of data captured in a real-world clinical practice environment, namely outside a conventional clinical trial setting. Through our expert analysis we transform the real-world data gathered in our observational studies into evidence; this can then be used to generate insights and drive understanding for our clients.

The need for real-world evidence is compelling – data from randomized clinical trials seldom fully reflect the impact of a treatment across the universe of patients. Real-world evidence helps translate trial findings into the environment in which the product will ultimately have to perform.

Our real-world evidence is based entirely on data obtained in a clinical practice setting. We do not advocate the use of uncontrolled / unmonitored ‘real life’ feedback found on social media as a basis for commercial or scientific decision-making.